Neovici Holding AB (publ)
Research Neovici Holding AB (publ) (IDLDX) on Bullrun: market cap SEK 94.68M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIDLDX
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencySEK
- Market capSEK 94.68M
- Financial periodQ1 2026
- RevenueSEK 16.74M
- Net incomeSEK 1.21M
- Free cash flowSEK 2.14M
- Gross margin65.6%
Valuation Snapshot
latest market cap is SEK 94.68M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 53.13M | -SEK 31.76M | -SEK 9.12M | 33.5% | -0.13 | SEK 36.57M | SEK 13.24M | SEK 148.16M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | SEK 94.68M | n/a | n/a | n/a |
About Neovici Holding AB (publ)
IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. Its vitro diagnostic biomarkers are used in breast, bladder, and prostate cancer therapies.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Neovici Holding AB (publ)'s market cap?
Neovici Holding AB (publ)'s market capitalization is SEK 94.68M.
What does Neovici Holding AB (publ) do?
IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. Its vitro diagnostic biomarkers are used in breast, bladder, and prostate cancer therapies. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) in May 2025.